

## REFERENCES

- Agrawal S and Kandimalla ER. Medical chemistry and therapeutic potential of CpG DNA. *Trends Mol Med* 2002; 8: 114-21.
- Alain B, Bruno D, Remy D, *et al.* A simple and convenient microtiter plate assay for the detection of bactericidal antibodies to *Vibrio cholerae* O1 and *Vibrio cholerae* O139. *J Microbiol Methods* 2003; 55: 745-53.
- Albert MJ. *Vibrio cholerae* O139 Bengal. *J Clin Microbiol* 1994; 32: 2345-9.
- Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. *Immunobiology* 1993; 187: 430-46.
- An H, Xu H, Yu Y, *et al.* Up-regulation of TLR9 gene by LPS in mouse macrophages via activation of NF- $\kappa$ B, ERK and p38 MAPK signal pathways. *Immunol Lett* 2002; 81: 165-9.
- Arulanandam BP, O'Toole M and Metzger WD. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. *J Infect Dis* 1999; 180: 940-9.
- Audibert FM and Lise LD. Adjuvants: current status, clinical perspectives and future prospects. *Immunol Today* 1993; 14: 281-4.
- Baca-Estrada ME. Intranasal immunization with liposome-formulated *Yersinia pestis* vaccine enhances mucosal immune responses. *Vaccine* 2000; 18: 2203-11.
- Baca-Estrada ME, Foldvari M and Snider M. Induction of mucosal immune responses by administration of liposome-antigen formations and IL-12. *J Interferon Cytokine Res* 1999; 19: 455-62.
- Barua D and Merson MH. Prevention and control of cholera. In: Barua D, Greenough III WB, eds. *Cholera*. New York: Plenum 1992: 329-49.
- Barrett TJ and Blake PA. Epidemiological usefulness of changes in hemolytic activity of *Vibrio cholerae* biotype El Tor during the seventh pandemic. *J Clin Microbiol* 1981; 13: 126-9.
- Bellamy JE, Knop J, Steele EJ, Chaicumpa W and Rowley D. Antibody cross-linking as a factor in immunity to cholera in infant mice. *J Infect Dis* 1975; 132: 181-8.
- Benenson AS. Cholera. In: Benenson AS. *Control of communicable disease in man*, 15th eds. Washington, DC: American Public Health Association, 1990: 89-94.

- Bergmann CK and Waldman HR. Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with a lipoidal amine (avridine). *Int Arch Allergy Appl Immunol* 1988; 87: 334-45.
- Boyaka NP, Marinaro M, Jackson JR, Menon S, Jirillo E and McGhee RJ. IL-12 is an effective adjuvant for induction of mucosal immunity. *J Immunol* 1999; 162: 122-8.
- Briskin M, Rott L and Butcher EC. Structural requirements for mucosal vascular addressin binding to its lymphocyte receptors  $\alpha 4\beta 7$ , common themes among integrin-Ig family interaction. *J Immunol* 1996; 156: 719-26.
- Briskin M, Winsor-Hines D, Shyjan A, *et al.* Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. *Am J Pathol* 1997; 151: 97-110.
- Broza M and Halpern M. Pathogen reservoirs: *Chironomid* egg masses and *Vibrio cholerae*. *Nature* 2001; 412: 40.
- Butcher EC and Picker LJ. Lymphocyte homing and homeostasis. *Science* 1996; 272: 60-6.
- Chaicumpa W, Chaisri U, Tapchaisri P, Chongsa-nguan M and Pongponratn E. Oral vaccine against cholera prepared from *V. cholerae* antigens. *Southeast Asian J Trop Med Public Health* 1987; 18: 142-8.
- Chaicumpa W, Chongsa-nguan M, Kalambahari T, *et al.* Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. *Vaccine* 1998; 16: 678-84.
- Chaicumpa W, Parairo JR, New RRC, Pongponratn E, Ruangkunaporn Y, and Tapchaisri P. Immunogenicity of liposome-associated oral cholera vaccine prepared from combined *Vibrio cholerae* antigens. *Asian Pac J Allergy Immunol* 1990; 8: 87-94.
- Chaing SL and Mekalanos JJ. *rfb* mutation in *V. cholerae* do not affect surface production of toxin-coregulated pili but still inhibit intestinal colonization. *Infect Immun* 1999; 67: 976-80.
- Chaisri U. Synergistic protection of anti-cell associated haemagglutinin and antitoxin against cholera. An M.Sc. (Tropical Medicine) thesis, Faculty of Tropical Medicine, Mahidol University, Bangkok, 1987.

- Champion GA, Neely MN, Brennan MA and DiRita VJ. A branch in the ToxR regulatory cascade of *Vibrio cholerae* revealed by characterization of *toxT* mutant strains. *Mol Microbiol* 1997; 23: 323-31.
- Chen H. Recent advances in mucosal vaccine development. *J Control Release* 2000; 67: 117-28.
- Chen H and Langer R. Oral particulate delivery: status and future trends. *Adv Drug Del Rev* 1998; 34: 339-50.
- Chen H, Torchilin V and Langer R. Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability. *J Control Release* 1996; 42: 263-72.
- Chiavelli AD, Marsh WJ and Taylor KR. The mannose-sensitive hemagglutinin of *Vibrio cholerae* promotes adherence to zooplankton. *Appl Environ Microbiol* 2001; 67: 3220-5.
- Childers NK. A controlled clinical study of the effect of the nasal immunization with a *Streptococcus mutans* alone or incorporated into liposomes on the induction of immune responses. *Infect Immun* 1999; 67: 618-23.
- Chongsa-nguan M, Chaicumpa W, Moolasart P, *et al.* *Vibrio cholerae* O139 Bengal in Bangkok. *Lancet* 1993; 342: 430-1.
- Chongsa-nguan M, Chaicumpa W, Ruangkunaporn Y and Looareesuwan S. Immunogenicity of two formulations of oral cholera vaccines in Thai volunteers. *Vaccine* 1991; 9: 53-9.
- Chu RS, Askew D, Noss EH, Tobian A, Krieg AM and Harding CV. CpG oligonucleotides down-regulate macrophage class II antigen processing. *J Immunol* 1999; 163: 1188-94.
- Claassen E and Boersma WJA. Characteristics and practical use of new-generation adjuvants as an acceptable alternative to Freund's complete adjuvant. *Res Immunol* 1992; 143: 475-7.
- Cleland JL. Single-administration vaccines: controlled-release technology to mimic repeated immunizations. *Trends Biotechnol* 1999; 17: 25-9.
- Clemens JD, Sack DA, Harris JR, *et al.* Field trial of oral cholera vaccines in Bangladesh. *Lancet* 1986; 2: 124-7.
- Clemens JD, Sack DA, Harris JR, *et al.* Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. *Lancet* 1990; 335: 270-3

- Cohen J, Schwartz T, Klasmer R, Pridan D, Ghalayini H and Davies MA. Epidemiology aspects of cholera El Tor outbreak in non-endemic area. *Lancet* 1971; 11: 86-9.
- Colwell RR. Global climate and infectious disease: The cholera paradigm. *Science* 1996; 274: 2025-31.
- Conway M. Protection against *Bordetella pertussis* infection following parenteral or oral immunization with antigens entrapped in biodegradable polymers: effect of formulation and route of immunization on induction of Th1 and Th2 cells. *Vaccine* 2001; 19: 1940-50.
- Coster TS, Killeen KP, Waldor MK, *et al.* Safety, immunogenicity, and efficacy of live attenuated *Vibrio cholerae* O139 vaccine prototype. *Lancet* 1995; 345: 949-52.
- Cowell RR and Spira WM. The ecology of *Vibrio cholerae*. In: Barua D and Greenough III WB, editors. *Cholera*. New York: Plenum; 1992: 107-27.
- Cox CJ and Coulter R A. Adjuvants- a classification and review of their modes of action. *Vaccine* 1997; 15: 248-56.
- Crawford JA, Kaper JB and DiRita VJ. Analysis of ToxR-dependent transcription activation of *ompU*, the gene encoding a major envelope protein in *V. cholerae*. *Mol Microbiol* 1998; 29: 235-46.
- Dalsgaard K. Saponin adjuvant III, isolation of substance from *Quillaja saponaria* Molina with adjuvant activity in foot and mouth disease. *Arch Gesamte Virusforsch* 1974; 44: 243-54.
- Dalsgaard K. A study of the isolation and characteration of the saponin Quil A, evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle against foot-and-mouth disease. *Acta Vet Scand* 1978; 69: 1-40.
- DiRita VJ, Neely M, Taylor RK and Bruss PM. Differential expression of the ToxR regulon in classical and El Tor biotypes of *Vibrio cholerae* is due to biotype-specific control over *toxT* expression. *Proc Natl Acad Sci USA* 1996; 93: 7991-5.
- Edelman R. Vaccine adjuvants. *Rev Infect Dis* 1980; 2: 370-83.

- Ehrhardt RO, Strober W and Harriman GR. Effect of transforming growth factor (TGF- $\beta$  $\delta$ ) on IgA isotype expression. TGF- $\beta$  $\delta$  induces a small increase in sIgA<sup>+</sup> B cells regardless of the method of B cell activation. *J Immunol* 1992; 148: 3830-6.
- Eldridge HJ, Hammond JC, Meulbroek AJ, Staas KJ, Gilley MR, and Tice RT. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. *J Controlled release* 1990; 11: 205-14.
- El Guink N, Kris RM, Goodman-Snitkoff G, Small PA and Mannino RJ. Intranasal immunization with proteoliposomes protects against influenza. *Vaccine* 1989; 7: 147-51.
- Farstad IN, Halstensen TS, Lien B, Hkilstad PJ, Lazarovits AI and Brandtzaeg P. Distribution of  $\beta$ 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue. *Immunology* 1996; 89: 227-37.
- Faruque SM, Albert MJ and Mekalanos JJ. Epidemiology, genetics, and ecology of toxigenic *Vibrio cholerae*. *Microbiol Mol Biol Rev* 1998; 62: 1301-14.
- Faruque SM, Ahmed MK, Siddique KA, Zaman K, Alim RMAR and Albert MJ. Molecular analysis of toxigenic *Vibrio cholerae* O139 Bengal isolated in Bangladesh between 1993 and 1996: evidence for the emergence of a new clone of the Bengal vibrios. *J Clin Microbiol* 1997; 35: 2299-306.
- Fasano A, Baudry B, Pumphlin DW, *et al.* *Vibrio cholerae* produces a second enterotoxin, which affects intestinal tight junctions. *Proc Natl Acad Sci USA* 1991; 88: 5242-6.
- Foster N. *Ulex europaeus* 1 lectin targets microspheres to mouse Peyer's patch M-cells *in vivo*. *Vaccine* 1998; 16: 536-41.
- Freunds J, Casals J and Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. *Proc Soc Exp Biol Med* 1937; 37: 509-13.
- Giudice DG, Pizza M and Rappuoli R. Mucosal delivery of vaccines. *Methods* 1999; 19: 148-55.
- Glass R, Huq I and Yunus M. Emergence of multiply antibiotic-resistant *V. cholerae* in Bangladesh. *J Infect Dis* 1980; 142: 939-42.

- Gogame R and Greenough III BW. Cholera in Africa: a message for the West. *Ann Intern Med* 1975; 82: 101-6.
- Gregoriadis G. Immunological adjuvants: a role for liposomes. *Immunol Today* 1990; 11: 89-97.
- Gupta RK. Aluminum compounds as vaccine adjuvants. *Adv Drug Deliv Rev* 1998; 32: 155-72.
- Gupta RK, Chang AC, Griffin P, Rivera R and Siber GR. *In vivo* distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing <sup>14</sup>C-labelled tetanus toxoids. *Vaccine* 1996; 14: 1412-6.
- Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S and Gupta CK. Adjuvants- a balance between toxicity and adjuvanicity. *Vaccine* 1993; 11: 293-306.
- Gupta RK and Siber GR. Comparison of adjuvant activities of aluminum phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. *Biologicals* 1994; 22: 53-63.
- Gupta RK and Siber GR. Adjuvants for human vaccines- current status, problems and future prospects. *Vaccine* 1995; 13: 1263-76.
- Hacker H. Signal transduction pathways activated by CpG DNA. *Curr Top Microb Immunol* 2000; 247: 77-92.
- Hartmann G and Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. *J Immunol* 2000; 164: 944-52.
- Hemmi H, Takeuchi O, Kawai T, *et al.* A Toll-like receptor recognizes bacterial DNA. *Nature* 2000; 408: 740-5.
- Heritage PL. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes. *Immunology* 1998; 93: 249-56.
- Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK and Levine MM. Toxin, toxin-coregulated pili, and the *toxR* regulon are essential for *Vibrio cholerae* pathogenesis in human. *J Exp Med* 1988; 168: 1487-92.
- Hilleman MR. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. *Prog Med Virol* 1966; 8: 131-82.

- Holmgren J and Svennerholm A. Development of oral vaccines against cholera and enterotoxinogenic *Escherchia coli* diarrhea. *J Infect Dis (Suppl)* 1990; 76: 47-53.
- Honda T and Finkelstein RA. Purification and characterization of a hemolysin produced by *Vibrio cholerae* biotype El Tor; another toxic substance produced by cholera vibrios. *Infect Immun* 1979; 26: 1020-7.
- Hu FK, Ekstrom J, Merza M, Lovgren-Bengtsson K and Morcein B. Induction of antibody responses in the common mucosal immune system by respiratory syncytial virus immunomodulating complexes. *Med Microbiol Immunol* 1999; 187: 191-8.
- Hunter R, Olsen M and Buynitzky S. Adjuvant activity of non-ionic block copolymers. IV. effect of molecular weight and formulation on titer and isotype of antibody. *Vaccine* 1991; 9: 250-6.
- Huq A, Colwell RR, Rahmann R, *et al.* Detection of *Vibrio cholerae* O1 in the aquatic environment by fluorescent-monoclonal antibody and culture methods. *Appl Environ Microbiol* 1990; 56: 2370-3.
- Ichinose Y, Yamamoto K, Nakasone N, *et al.* Enterotoxicity of El Tor-like hemolysin of non-O1 *Vibrio cholerae*. *Infect Immun* 1987; 55: 1090-3.
- Illum L. Chitosan and its use as a pharmaceutical excipient. *Pharm Res* 1995; 15: 1326-31.
- Iredeli JR, Stroehner UH, Ward HM and Manning PA. Lipopolysaccharide O-antigen expression and the effect of its absence on virulence in *rfb* mutants of *V. cholerae* O1. *FEMS Immuno Med Microbiol* 1998; 20: 45-54.
- Islam MS, Drasar SB, and Sack BR. The aquatic environment as reservoirs of *V. cholerae*. *J Diarrhoeal Dis Res* 1994; 11: 197-206.
- Jertborn M, Svennerholm A-M, and Holmgren J. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. *Vaccine* 1992; 10: 130-2.
- Jeurissen HS, Sminia T, and Beuvery CE. Induction of mucosal immunoglobulin A immune response by preparations of *Neisseria gonorrhoeae* porin proteins. *Infect Immun* 1987; 55: 253-7.

- Johnson AG, Gaines S and Landy M. Studies on the O antigen of *Salmonella typhosa* V enhancement of antibody response to protein antigens by the purified lipopolysaccharide. *J Exp Med* 1956; 103: 225-46.
- Kaisho T and Akira S. Dendritic-cell function in Toll-like receptor and MyD88 knockout mice. *Trends Immunol* 2001; 22: 78-83.
- Kantele A, Kantele JM, Savilahti E, *et al.* Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. *J Immunol* 1997; 158: 574-9.
- Kiyoshi T and Shizuo A. TLR signaling pathways. *Seminars in Immunol* 2004; 16: 3-9.
- Kovacikova G, and Skorupski K. A *Vibrio cholerae* LysR homolog, AphB, cooperates with AphA at the *tcpPH* promoter to activate expression of the ToxR virulence cascade. *J Bacteriol* 1999; 181: 4250-6.
- Levine MM. South America: the return of cholera. *Lancet* 1991; 338: 45-6.
- Levine MM, Kaper JB, Herrington D, *et al.* Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD103 and CVD103-HgR. *Lancet* 1988; 2: 467-70.
- Levine MM and Tacket CO. Recombinant live cholera vaccines. In: Wachsmuth IK, Blake PA, Olsvik O, eds. *Vibrio cholerae* and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology. 1994: 395-413.
- Li CC, Crawford JA, Dirita VJ and Kaper JB. Molecular cloning and transcription regulation of *ompT*, a ToxR-repressed gene in *V. cholerae*. *Mol Microbiol* 2000; 35: 189-203.
- McCluskie JM and Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. *J Immunol* 1998; 161: 4463-6.
- McCluskie MJ and Davis HL. CpG DNA as mucosal adjuvant. *Vaccine* 1999; 18: 231-7.



- McCluskie MJ and Davis HL. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligonucleotides as adjuvants. *Vaccine* 2001; 19: 413-22.
- McCluskie MJ, Weeratna RD, Clemens JD and Davis HL. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of *Escherichia coli* as adjuvants. *Vaccine* 2001; 19: 3759-68.
- McGhee JR, Lamm ME and Strober W. Mucosal immune responses. In: McGhee JR, editor. *Mucosal Immunology*; 1999; 485-506.
- McNeela EA. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. *Vaccine* 2000; 19: 1188-98.
- Medzhitov R. Toll-like receptors and innate immunity. *Nat Rev Immunol* 2001; 1: 135-45.
- Mekalanos JJ, Rubin JE and Waldor KM. Cholera: molecular basis for emergence and pathogenesis. *FEMS Immuno Med Microbiol* 1997; 18: 241-8.
- Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. *J Clin Microbiol* 1987; 7: 265-76.
- Michalek SM, O'Hagan DT, Gould-Fogerite S, Rimmelzwaan GF and Osterhaus ADME. Antigen delivery systems: nonliving microparticles, liposomes, cochleates, and ISCOMS. In: McCluskie MJ, editor. *Mucosal Immunology*; 1999; 759-78.
- Moldoveanu Z, Love-homan L, Huang WQ and Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. *Vaccine* 1998; 16: 1216-24.
- Monsur KA, Rizvi SSH and Huq MI. Effect of Mukerjee's Group IV phage on El Tor vibrios. *Bull WHO* 1965; 32: 211-6.
- Moore A. The adjuvant combination of monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. *Vaccine* 1999; 17: 2517-27.
- Morcein B. The ISCOM: an immunostimulatory systems. *Immunol Lett* 1990; 25: 283-4.

- Mowat MA, Maloy JK and Donachic MA. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. *Immunology* 1993; 80: 527-34.
- Mukerjee S and Roy G. Evaluation of tests for differentiating *Vibrio cholerae* and El Tor vibrios. *Ann Biochem Exp Med* 1961; 21: 129-32.
- Mukhopadhyay AK, Basu A, Garg P, *et al.* Molecular epidemiology of reemergent *Vibrio cholerae* O139 Bengal in India. *J Clin Microbiol* 1998; 36: 2149-52.
- Nair GB, Shimada T, Kurazono H, *et al.* Characterization of phenotypic, serotypic, and toxigenic traits of *Vibrio cholerae* O139 Bengal. *J clin Microbiol* 1994; 32: 2775-9.
- Nalin DR. Cholera, copepods, and chitinase. *Lancet* 1976; 7: 952-8.
- Nalin DR, Daya V, Reid A, Levine MM and Cisneros L. Adsorption and growth of *Vibrio cholerae* on chitin. *Infect Immun* 1979; 25: 768-70.
- Nataro JP and Levine MM. Enteric bacterial vaccines: *Salmonella*, *Shigella*, Cholera, *Escherichia coli*. In: McGhee JR, editor. *Mucosal Immunology*; 1999; 851-66.
- Nesper J, Lauriano CM, Klose KE, Kraib A and Reid A. Characterization of *V. cholerae* O1 El Tor *galU* and *galE* mutants: influence on lipopolysaccharide, colonization and biofilm-formation. *Infect Immun* 2001; 69: 435-45.
- Novitsky JS and Morita RY. Possible strategy for the survival of marine bacteria under starvation conditions. *Mar Biol* 1978; 48: 289-95.
- O'Hagan DT, MacKichan ML and Singh M. Recent developments in adjuvants for vaccines against infectious diseases. *Biomol Eng* 2001; 18: 69-85.
- Okada J, Cohen S and Langer R. *In vitro* evaluation of polymerized liposomes as an oral drug delivery system. *Pharm Res* 1995; 12: 576-82.
- Organization PAH. Cholera situation in the Americas. *Epidemiol Bull* 1991; 12: 1-4.
- Pal SC. Laboratory diagnosis. In: Barua D and Greenough BW, editors. *Cholera*. 3 ed. New York; 1992; 229-51.
- Pearson GDN, Woods S, Chiang SL and Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. *Proc Natl Acad Sci USA* 1993; 90: 3750-4.

- Pierce NF, Cray WC Jr, Sacci JB Jr, Craig JP, Germanier R and Furer E. Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. *Infect Immun* 1983; 40: 1112-8.
- Pierce NF and Sacci BJ. Enhanced mucosal priming by cholera toxin and procholeragenoid with a lipoidal amine adjuvant (avridine) delivered in liposomes. *Infect Immun* 1984; 44: 469-73.
- Provenzano D and Klose KE. Altered expression of the *toxR*-regulated porins *ompU* and *ompT* diminishes *Vibrio cholerae* bile resistance, virulence factors expression, and intestinal colonization. *Proc Natl Acad Sci USA* 2000; 97: 10220-4.
- Provenzano D, Lauriano CM and Klose KE. Characteristic of the role of the *ToxR*-modulated outer membrane porins *OmpU* and *OmpT* in *Vibrio cholerae*. *J Bacteriol* 2001; 183: 3652-62.
- Ramamurthy T, Garg S, Sharma R, *et al.* Emergence of a novel strain of *Vibrio cholerae* with epidemic potential in Southern and Eastern India. *Lancet* 1993; 341: 703-4.
- Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiphtherique. *Bull Soc Centr Med Vet* 1925; 101: 227-34.
- Ramon G. Procedres pour acroitre la production des antitoxines. *Ann Institut Pasteur* 1926; 40: 1-10.
- Reidl J and Klose KE. *Vibrio cholerae* and cholera: out of the water and into the host. *FEMS Microbiol Rev* 2002; 26: 125-39.
- Relyveld EH, Bizzini B and Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. *Vaccine* 1998; 16: 1016-23.
- Ries AA, Vugia JD, Beingolea L, *et al.* Cholera in Piura, Peru: a modern urban epidemic. *J Infect Dis* 1992; 166: 1429-33.
- Roy K. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. *Nat Med* 1999; 5: 387-91.
- Ryan ET and Calderwood SB. Cholera vaccines. *Clin Infect Dis* 2000; 31: 561-5.
- Ryan JE, Daly ML and Mills HGK. Immunomodulators and delivery systems for vaccination by mucosal routes. *Trends Immunol* 2001; 19: 293-304.

- Saha PK. Non-toxigenic *Vibrio cholerae* O1 serotype Inaba biotype El Tor associated with a cluster of cases of cholera in Southern India. *J Clin Microbiol* 1996; 34: 1114-7.
- Saisongkorh W. DNA amplication for *Vibrio cholerae* O:139 detection. M. Sc. Thesis, Mahidol University, Bangkok, 2000.
- Salkowski CA. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. *Infect Immun* 1997; 65: 3239-47.
- Sanchez JL, Trofa AF, Taylor DN, *et al.* Safety and immunogenicity of the oral, whole cell-recombinant B subunit cholera vaccine in North American volunteers. *J Infect Dis* 1993; 167: 1446-9.
- Sanchez JL, Vasquez B, Begue RE, *et al.* Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. *Lancet* 1994; 344: 1273-6.
- Satcher D. Emerging infections: getting ahead of the cure. *Emerg Infect Dis* 1995; 1: 1-6.
- Scheepers K and Beeht H. Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes. *Med Microbiol Immunol* 1994; 183: 265-78.
- Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. *Adv Drug Deliv Rev* 2000; 44: 119-34.
- Schuhmacher DA and Klose KE. Environmental signals modulate *toxT*-dependent virulence factor expression in *Vibrio cholerae*. *J Bacteriol* 1999; 181: 1508-14.
- Seong SY. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with *Streptococcus pneumoniae*. *Infect Immun* 1999; 67: 3587-92.
- Sharma C. Molecular analysis of non-O1, non-139 *Vibrio cholerae* associated with an unusual upsurge in the incidence of cholera-like disease in Calcutta, India. *J Clin Microbiol* 1998; 36: 756-63.
- Shaw CE, Hall RH and Parker RK. *Vibrio cholerae* O395 *tcpA* pilin gene sequence and comparison of predicted protein structural to those of type 4 pilins. *Infect Immun* 1990; 58: 3042-9.

- Shi Y, HogenEsch H, Regnier FE and Hem SL. Detoxification of endotoxin by aluminum hydroxide adjuvant. *Vaccine* 2001; 19: 1747-52.
- Shimada T, Nair GB, Deb CB, Albert MJ, Sack BR and Takeda Y. Outbreak of *Vibrio cholerae* non-O1 in India and Bangladesh. *Lancet* 1993; 341: 1347.
- Siddique AK, Salam A, Islam SM, *et al.* Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. *Lancet* 1995; 345: 359-61.
- Skhek PN and Sabiston BH. Immune response mediated by liposome-associated protein antigen. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiality. *Immunology* 1982; 47: 627-32.
- Snow J. On the mode of communication of cholera. In: Churchill J, editor. London, England; 1855.
- Sun DX, Mekalanos JJ and Taylor RK. Antibodies directed against the toxin-coregulated pilus isolated from *Vibrio cholerae* provide protection in the infant mouse experimental cholera model. *J Infect Dis* 1990; 161: 1231-6.
- Sun S, Kishimoto H and Sprent J. DNA as adjuvant; capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. *J Exp Med* 1998; 187: 1145-50.
- Swerdlow DL and Ries AA. *Vibrio cholerae* non-O1- the eighth pandemic. *Lancet* 1993; 342: 382-3.
- Tabtieng R, Wattanasri S and Echeverria P. An epidemic of *V. cholerae* El Tor Inaba resistant to several antibiotics with a conjugative group O plasmid coding for type II dihydrofolate reductase in Thailand. *Am J Trop Med Hyg* 1989; 41: 680-6.
- Tacket CO, Losonsky G, Nataro JP, *et al.* Initial clinical studies of CVD112 *Vibrio cholerae* O139 live oral vaccine: safety and efficacy against experimental challenge. *J Infect Dis* 1995; 172: 883-6.
- Tacket CO, Losonsky G, Nataro JP, *et al.* Safety and immunogenicity of oral cholera vaccine candidate CVD110, a  $\Delta$ ctxA,  $\Delta$ zot,  $\Delta$ ace derivative of El Tor Ogawa *Vibrio cholerae*. *J Infect Dis* 1993; 168: 1536-40.

- Tauxe RV and Blake PA. Epidemic cholera in Latin America. JAMA 1992; 267: 1388-90.
- Taylor RK, Miller VL, Furlong DB and Mekalanos JJ. Use of *phoA* gene fusion to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci USA 1987; 84: 2833-7.
- Tiisala S, Paavonen T and Renkonen R.  $\alpha\epsilon\beta 7$  and  $\alpha 4\beta 7$  integrins associated with intraepithelial and mucosal homing are expressed on macrophages. Eur J Immunol 1995; 25: 411-7.
- Trach DD, Clemens JD, and Ke NT. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997; 349: 231-5.
- Trucksis M, Galen JE, Michalski J, Fasano A and Kaper JB. Accessory cholera enterotoxin (Ace), the third toxin of a *Vibrio cholerae* virulence cassette. Proc Natl Acad Sci USA 1993; 90: 5267-71.
- Ulanova M, Tarkowski A, Hahn-Zoric M and Hanson LA. Adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001; 69: 1151-9.
- Van Ginkel FW, Nguyen HH and McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis 2000; 6: 123-32.
- Waldman RH, Bencic Z and Sinha R. Cholera immunology. II. Serum and intestinal secretion antibody response after naturally-occurring cholera. J Infect Dis 1972; 126: 401-7.
- Waldor KW and Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 1996; 272: 1910-4.
- Watari S, Han M and Tana KH. Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposome. J Vet Med Sci 1998; 60: 1047-50.
- Watnick P and Kolter R. Steps in the development of a *Vibrio cholerae* El Tor biofilm. Mol Microbiol 1999; 34: 586-95.
- Watnick PI, Lauriano CM, Klose KE, Croal L and Kolter R. The absence of a flagellum leads to altered colony morphology, biofilm development and virulence in *Vibrio cholerae* O139. Mol Microbiol 2001; 39: 223-35.

- Westphal O and Jann K. Bacterial lopolysaccharide extraction with phenol-water and further application of the procedure. *Methods Carbohy Chem* 1965; 5: 83
- Yildiz FH and Schoolnik GK. *Vibrio cholerae* O1 El Tor: identification of gene cluster required for the rugose colony type, exopolysaccharide production, chlorine resistance, and biofilm formation. *Proc Natl Acad Sci USA* 1999; 96: 4028-33.
- Zinkernagel R, Ehl S, Aichele P, Oehen S, Kundig T and Hengartner H. Antigen localization regulates immune response in a dose and time-dependent fashion: a geographical view of immune reactivity. *Immunol Rev* 1997; 156: 199–209.